

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Katsuya MATSUDA, et al.
 Serial No.: 09/807,190
 Filed: April 10, 2001
 For: POLYMER COMBINING WITH...



Art Unit: 1615
 Confirmation No.: 4190
 Examiner: P. KULKOSKY
 Washington, D.C.
 Atty.'s Docket: MATSUDA13
 Date: August 29, 2001

RECEIVED
 SEP 04 2001
 TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:

Transmitted herewith is an [XX] Amendment []
 in the above-identified application.

- [] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
 [] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
 [] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fee	Rate	Additional Fee
Total	28	Minus	20	8	x 9	\$	x18	\$ 144.00
Indep.	3	Minus	3	0	x40	\$	x80	\$
First Presentation of Multiple Dependent Claim					135	\$	+270	\$
TOTAL ADDITIONAL CLAIMS FEE						\$	Total	\$ 144.00

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.
 The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

- [] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity
 Response Filed Within
 [] First - \$ 55.00
 [] Second - \$195.00
 [] Third - \$445.00
 [] Fourth - \$695.00

Other Than Small Entity
 Response Filed Within
 [] First - \$ 110.00
 [] Second - \$ 390.00
 [] Third - \$ 890.00
 [] Fourth - \$1390.00

[] Less fees (\$) already paid for months extension of time on .

- [] Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

[] A check in the amount of \$ is attached (check no.).


[XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ 144.00 is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By:
 John H. Kornbaur
 Registration No. 25,884



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: MATSUDA13

In re Application of:

Katsuya MATSUDA, et al.

Serial No.: 09/807,190

Filed: April 10, 2001

For: POLYMER COMBINING WITH
PHOSPHORIC ACID AND...

) Art Unit: 1615

) Examiner: P. KULKOSKY

) Confirmation No. 4190

) Washington D.C.

) August 29, 2001

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

In response to the Office Action of May 31, 2001,
please enter the following Amendment:

IN THE SPECIFICATION

Page 3, please amend the second paragraph as
follows:

When administered orally, phosphate-binding polymers adsorb phosphorus in foods and are excreted into the feces to thereby inhibit the absorption of phosphorus via the digestive tracts, thus controlling the serum phosphorus level. These phosphate-binding polymers are taken in a relatively large single dose, i.e., from 1 to 2 g. Because they react with water and thus swell rapidly, the phosphate-binding polymers can be hardly taken as such. What is more, tablets prepared by compressing the conventional phosphate-binding polymers without additives have only insufficient tablet hardness, so it has been essential to incorporate substantial amounts of crystalline cellulose and/or low substituted hydroxypropyl

TECH CENTER 1600/2900

SEP 04 2001

RECEIVED

5/B
A. H. H. H. H.
9/25/01